| Форма представления | Статьи в зарубежных журналах и сборниках |
| Год публикации | 2024 |
| Язык | английский |
|
Бондарь Оксана Викторовна, автор
Гнездилов Олег Иванович, автор
Павельев Роман Сергеевич, автор
Пугачев Михаил Владимирович, автор
Штырлин Юрий Григорьевич, автор
|
|
Кадырова Айсылу Сулеймановна, автор
Карут Рауда , автор
|
|
Алрхмун Салех , автор
Мохаммад Тараа , автор
|
| Библиографическое описание на языке оригинала |
Karwt R. Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study / R. Karwt, O.V. Bondar, M.V. Pugachev, T. Mohammad, R.S. Pavelyev, S. Al-rhmoun, O.I. Gnezdilov, Y.G. Shtyrlin / Life. 2024; 14(3):282. PMID: 38541608 PMCID: PMC10970924 DOI: 10.3390/life14030282 |
| Аннотация |
Doxorubicin (DOX) is a prevalent anticancer agent; however, it is unfortunately characterized
by high cardiotoxicity, myelosuppression, and multiple other side effects. To overcome DOX
limitations, two novel pyridoxine-derived doxorubicin derivatives were synthesized (DOX-1 and
DOX-2). In the present study, their antitumor activity and mechanism of action were investigated.
Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin
molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to
doxorubicin and a promising safety profile for conditionally normal cells. However, the compound
with a C1 linker (DOX-1) was not characterized by selectivity of antitumor action. It was revealed that
DOX-2 obstructs cell cycle progression, induces apoptosis via the mitochondrial pathway without
the development of necrosis, and showcases antioxidant capabilities, underlining its cell-regulatory
roles. In contrast to doxorubicin's DNA-centric mechanism, DOX-2 does not interact with nuclear
DNA. Given these findings, DOX-2 presents a new promising direction in cancer therapeutics, which
is deserving of further in vivo exploration. |
| Ключевые слова |
doxorubicin; anticancer agents; doxorubicin derivatives; pyridoxine; vitamin B6; apoptosis induction; DNA intercalation; cell-cycle arrest; antioxidants |
| Название журнала |
Life
|
| URL |
https://www.mdpi.com/2075-1729/14/3/282 |
| Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку |
https://repository.kpfu.ru/?p_id=302492 |
| Файлы ресурса | |
|
|
Полная запись метаданных  |
| Поле DC |
Значение |
Язык |
| dc.contributor.author |
Бондарь Оксана Викторовна |
ru_RU |
| dc.contributor.author |
Гнездилов Олег Иванович |
ru_RU |
| dc.contributor.author |
Павельев Роман Сергеевич |
ru_RU |
| dc.contributor.author |
Пугачев Михаил Владимирович |
ru_RU |
| dc.contributor.author |
Штырлин Юрий Григорьевич |
ru_RU |
| dc.contributor.author |
Алрхмун Салех |
ru_RU |
| dc.contributor.author |
Мохаммад Тараа |
ru_RU |
| dc.contributor.author |
Кадырова Айсылу Сулеймановна |
ru_RU |
| dc.contributor.author |
Карут Рауда |
ru_RU |
| dc.date.accessioned |
2024-01-01T00:00:00Z |
ru_RU |
| dc.date.available |
2024-01-01T00:00:00Z |
ru_RU |
| dc.date.issued |
2024 |
ru_RU |
| dc.identifier.citation |
Karwt R. Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study / R. Karwt, O.V. Bondar, M.V. Pugachev, T. Mohammad, R.S. Pavelyev, S. Al-rhmoun, O.I. Gnezdilov, Y.G. Shtyrlin / Life. 2024; 14(3):282. PMID: 38541608 PMCID: PMC10970924 DOI: 10.3390/life14030282 |
ru_RU |
| dc.identifier.uri |
https://repository.kpfu.ru/?p_id=302492 |
ru_RU |
| dc.description.abstract |
Life |
ru_RU |
| dc.description.abstract |
Doxorubicin (DOX) is a prevalent anticancer agent; however, it is unfortunately characterized
by high cardiotoxicity, myelosuppression, and multiple other side effects. To overcome DOX
limitations, two novel pyridoxine-derived doxorubicin derivatives were synthesized (DOX-1 and
DOX-2). In the present study, their antitumor activity and mechanism of action were investigated.
Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin
molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to
doxorubicin and a promising safety profile for conditionally normal cells. However, the compound
with a C1 linker (DOX-1) was not characterized by selectivity of antitumor action. It was revealed that
DOX-2 obstructs cell cycle progression, induces apoptosis via the mitochondrial pathway without
the development of necrosis, and showcases antioxidant capabilities, underlining its cell-regulatory
roles. In contrast to doxorubicin's DNA-centric mechanism, DOX-2 does not interact with nuclear
DNA. Given these findings, DOX-2 presents a new promising direction in cancer therapeutics, which
is deserving of further in vivo exploration. |
ru_RU |
| dc.language.iso |
ru |
ru_RU |
| dc.subject |
|
ru_RU |
| dc.title |
Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives, in vitro Study |
ru_RU |
| dc.type |
Статьи в зарубежных журналах и сборниках |
ru_RU |
|
EN 
中文 
ES 
Карта сайта
